Based on such findings, we hypothesized that the increased secretion of leptin, TNF, and IL-6 together with the decreased secretion of adiponctin in perirenal adipocytes could be associated with the upgrade of angiogenesis signatures in RCC and might enhance drug delivery and improve patients’ response to anti-VEGF therapy (Figure 5B). The gene discussed is LEP; the disease is renal cell carcinoma.